Page 11234..1020..»

IGM Biosciences Enters into Exclusive Licensing Agreement with Medivir for Birinapant

By Dr. Matthew Watson

- IGM to Develop Birinapant in Combination with IGM-8444 for the Treatment of Solid Tumors - - IGM to Develop Birinapant in Combination with IGM-8444 for the Treatment of Solid Tumors -

See the rest here:
IGM Biosciences Enters into Exclusive Licensing Agreement with Medivir for Birinapant

To Read More: IGM Biosciences Enters into Exclusive Licensing Agreement with Medivir for Birinapant
categoriaGlobal News Feed commentoComments Off on IGM Biosciences Enters into Exclusive Licensing Agreement with Medivir for Birinapant | dataJanuary 12th, 2021
Read All

T2 Biosystems T2SARS-CoV-2™ Panel Proves Effective Amid Global Rise in Variants of the SARS-CoV-2 Virus

By Dr. Matthew Watson

Panel can detect multiple variants of the SARS-CoV-2 virus, including those most recently identified in the United Kingdom, South Africa, and the U.S.

Read more:
T2 Biosystems T2SARS-CoV-2™ Panel Proves Effective Amid Global Rise in Variants of the SARS-CoV-2 Virus

To Read More: T2 Biosystems T2SARS-CoV-2™ Panel Proves Effective Amid Global Rise in Variants of the SARS-CoV-2 Virus
categoriaGlobal News Feed commentoComments Off on T2 Biosystems T2SARS-CoV-2™ Panel Proves Effective Amid Global Rise in Variants of the SARS-CoV-2 Virus | dataJanuary 12th, 2021
Read All

Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units

By Dr. Matthew Watson

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

Here is the original post:
Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units

To Read More: Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units
categoriaGlobal News Feed commentoComments Off on Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units | dataJanuary 12th, 2021
Read All

Qilian International Holding Group Limited Announces Pricing of Initial Public Offering

By Dr. Matthew Watson

Jiuquan, China, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (the “Company”), a China-based pharmaceutical and chemical products manufacturer, today announced the pricing of its initial public offering ("Offering") of 5,000,000 ordinary shares at a public offering price of US$5.00 per share. The ordinary shares have been approved for listing on the Nasdaq Global Market and are expected to commence trading on January 12, 2021 under the ticker symbol “QLI”.

Read the original post:
Qilian International Holding Group Limited Announces Pricing of Initial Public Offering

To Read More: Qilian International Holding Group Limited Announces Pricing of Initial Public Offering
categoriaGlobal News Feed commentoComments Off on Qilian International Holding Group Limited Announces Pricing of Initial Public Offering | dataJanuary 12th, 2021
Read All

Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common…

By Dr. Matthew Watson

Basel, 12 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present updated overall survival (OS) data from the Phase III IMbrave150 study evaluating Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab), compared with sorafenib, in people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

Read more from the original source:
Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common...

To Read More: Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common…
categoriaGlobal News Feed commentoComments Off on Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common… | dataJanuary 12th, 2021
Read All

Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health

By Dr. Matthew Watson

- Collaboration with Richard Childs, M.D., yields potential first-ever antibodies targeting human endogenous retrovirus associated with renal cell carcinoma

Visit link:
Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health

To Read More: Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health
categoriaGlobal News Feed commentoComments Off on Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health | dataJanuary 12th, 2021
Read All

Addex to Present at the Baader Helvea Swiss Equities Conference

By Dr. Matthew Watson

Geneva, Switzerland, January 12, 2021 -  Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Tim Dyer, Chief Executive Officer, is scheduled to participate in the virtual Baader Helvea Swiss Equities Conference taking place on January 13 – January 15, 2021.

More:
Addex to Present at the Baader Helvea Swiss Equities Conference

To Read More: Addex to Present at the Baader Helvea Swiss Equities Conference
categoriaGlobal News Feed commentoComments Off on Addex to Present at the Baader Helvea Swiss Equities Conference | dataJanuary 12th, 2021
Read All

Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study

By Dr. Matthew Watson

REGULATED INFORMATION

Read more:
Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study

To Read More: Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study
categoriaGlobal News Feed commentoComments Off on Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study | dataJanuary 12th, 2021
Read All

iosBio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro™ oral vaccine platform technology for COVID-19  

By Dr. Matthew Watson

PRESS RELEASE

Original post:
iosBio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro™ oral vaccine platform technology for COVID-19  

To Read More: iosBio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro™ oral vaccine platform technology for COVID-19  
categoriaGlobal News Feed commentoComments Off on iosBio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro™ oral vaccine platform technology for COVID-19   | dataJanuary 12th, 2021
Read All

Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19

By Dr. Matthew Watson

SAN FRANCISCO and LONDON, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced an agreement with the U.K.-based AGILE initiative to evaluate VIR-7832 in patients with mild to moderate COVID-19 in a Phase 1b/2a clinical trial. VIR-7832 is a neutralizing COVID-19 antibody that preclinical data suggests has two distinguishing properties: an enhanced ability to clear infected cells and the potential to enhance virus-specific T-cell function, which could help treat and/or prevent COVID-19 infection.

View original post here:
Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19

To Read More: Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19
categoriaGlobal News Feed commentoComments Off on Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19 | dataJanuary 12th, 2021
Read All

BetterLife Provides Shareholder Update and 2021 Product Development Roadmap

By Dr. Matthew Watson

VANCOUVER, Jan. 11, 2021 (GLOBE NEWSWIRE) -- VANCOUVER, January 12, 2021 - BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections, is pleased to provide an overview of the Company’s primary plans for this calendar year to develop 3 novel therapeutic products, each addressing significant unmet needs with multi-billion dollar market potential.

Here is the original post:
BetterLife Provides Shareholder Update and 2021 Product Development Roadmap

To Read More: BetterLife Provides Shareholder Update and 2021 Product Development Roadmap
categoriaGlobal News Feed commentoComments Off on BetterLife Provides Shareholder Update and 2021 Product Development Roadmap | dataJanuary 12th, 2021
Read All

Recommendation by the Nomination Committee concerning the Board of Directors to be elected by the 2021 AGM of Orion Corporation

By Dr. Matthew Watson

ORION CORPORATION  STOCK EXCHANGE RELEASE 12 JANUARY 2021 at 10.15 EET

Originally posted here:
Recommendation by the Nomination Committee concerning the Board of Directors to be elected by the 2021 AGM of Orion Corporation

To Read More: Recommendation by the Nomination Committee concerning the Board of Directors to be elected by the 2021 AGM of Orion Corporation
categoriaGlobal News Feed commentoComments Off on Recommendation by the Nomination Committee concerning the Board of Directors to be elected by the 2021 AGM of Orion Corporation | dataJanuary 12th, 2021
Read All

Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities

By Dr. Matthew Watson

Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities

Read the rest here:
Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities

To Read More: Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities
categoriaGlobal News Feed commentoComments Off on Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities | dataJanuary 12th, 2021
Read All

Valneva in Advanced Discussions with European Commission to Supply up to 60 Million Doses of Inactivated, Adjuvanted COVID-19 Vaccine Candidate

By Dr. Matthew Watson

Saint-Herblain (France), January 12, 2021 – Valneva SE, a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need, today announced it is in advanced discussions with the European Commission (EC) for the supply of up to 60 million doses of its COVID-19 vaccine, VLA2001. VLA2001 is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe.

Read more from the original source:
Valneva in Advanced Discussions with European Commission to Supply up to 60 Million Doses of Inactivated, Adjuvanted COVID-19 Vaccine Candidate

To Read More: Valneva in Advanced Discussions with European Commission to Supply up to 60 Million Doses of Inactivated, Adjuvanted COVID-19 Vaccine Candidate
categoriaGlobal News Feed commentoComments Off on Valneva in Advanced Discussions with European Commission to Supply up to 60 Million Doses of Inactivated, Adjuvanted COVID-19 Vaccine Candidate | dataJanuary 12th, 2021
Read All

ProMIS Neurosciences Announces Strategic Priorities for 2021

By Dr. Matthew Watson

TORONTO and CAMBRIDGE, Mass., Jan. 12, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today an outline of its strategic priorities and action plan for 2021.

See the original post here:
ProMIS Neurosciences Announces Strategic Priorities for 2021

To Read More: ProMIS Neurosciences Announces Strategic Priorities for 2021
categoriaGlobal News Feed commentoComments Off on ProMIS Neurosciences Announces Strategic Priorities for 2021 | dataJanuary 12th, 2021
Read All

Adamas to Present at Upcoming H.C. Wainwright Conference

By Dr. Matthew Watson

EMERYVILLE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company’s Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright VIRTUAL BioConnect Conference, being held January 11 – 14, 2021.

See the article here:
Adamas to Present at Upcoming H.C. Wainwright Conference

To Read More: Adamas to Present at Upcoming H.C. Wainwright Conference
categoriaGlobal News Feed commentoComments Off on Adamas to Present at Upcoming H.C. Wainwright Conference | dataJanuary 5th, 2021
Read All

Syneos Health to Present at the 39th Annual J.P. Morgan Healthcare Conference

By Dr. Matthew Watson

MORRISVILLE, N.C., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced that Chief Executive Officer Alistair Macdonald is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 8:20 a.m. EST.

Read more here:
Syneos Health to Present at the 39th Annual J.P. Morgan Healthcare Conference

To Read More: Syneos Health to Present at the 39th Annual J.P. Morgan Healthcare Conference
categoriaGlobal News Feed commentoComments Off on Syneos Health to Present at the 39th Annual J.P. Morgan Healthcare Conference | dataJanuary 5th, 2021
Read All

aTyr Pharma Announces Positive Topline Results from Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications

By Dr. Matthew Watson

Study met primary safety endpoint in moderate to severe hospitalized COVID-19 patients.

Visit link:
aTyr Pharma Announces Positive Topline Results from Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications

To Read More: aTyr Pharma Announces Positive Topline Results from Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications
categoriaGlobal News Feed commentoComments Off on aTyr Pharma Announces Positive Topline Results from Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications | dataJanuary 5th, 2021
Read All

Genocea to Present at the H.C. Wainwright Virtual BioConnect Conference

By Dr. Matthew Watson

CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president and chief executive officer, will present a corporate overview at the H.C. Wainwright Virtual BioConnect Conference being held from January 11 – 14, 2021. A webcast of the on-demand presentation will be available on the investor section of the Genocea website at http://ir.genocea.com, beginning on Monday, January 11, 2021.

Originally posted here:
Genocea to Present at the H.C. Wainwright Virtual BioConnect Conference

To Read More: Genocea to Present at the H.C. Wainwright Virtual BioConnect Conference
categoriaGlobal News Feed commentoComments Off on Genocea to Present at the H.C. Wainwright Virtual BioConnect Conference | dataJanuary 5th, 2021
Read All

Checkmate Pharmaceuticals Announces Key Additions to Executive Management Team

By Dr. Matthew Watson

Robert F. Dolski appointed as Chief Financial Officer

Originally posted here:
Checkmate Pharmaceuticals Announces Key Additions to Executive Management Team

To Read More: Checkmate Pharmaceuticals Announces Key Additions to Executive Management Team
categoriaGlobal News Feed commentoComments Off on Checkmate Pharmaceuticals Announces Key Additions to Executive Management Team | dataJanuary 5th, 2021
Read All

Page 11234..1020..»